Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Omega Announces Third Quarter 2017 Financial Results; Increased Dividend Rate for 21st Consecutive Quarter

OHI

Omega Announces Third Quarter 2017 Financial Results; Increased Dividend Rate for 21 st Consecutive Quarter

Results Reflect Impairment Related to Orianna Portfolio

Omega Healthcare Investors, Inc. (NYSE:OHI) (the “Company” or “Omega”) today announced its results of operations for the three-month period ended September 30, 2017. The Company reported a net loss for the three-month period ended September 30, 2017 of ($137.5) million, or ($0.67) per common share. Funds From Operations (“FFO”) for the quarter was a deficit of ($46.8) million or ($0.24) per common share and Funds Available For Distribution (“FAD”) was $150.6 million.

FFO for the third quarter of 2017 includes $194.7 million in impairments on direct financing leases related to our Orianna Health Systems (“Orianna” and f/k/a ARK) portfolio, $11.9 million in provisions for uncollectible accounts, and $3.9 million of non-cash stock-based compensation expense. Adjusted FFO (“AFFO”), which excludes those three items, was $0.79 per common share for the three-month period ended September 30, 2017. FFO, AFFO and FAD are non-GAAP financial measures. For more information regarding FFO and AFFO, see the “Funds From Operations” schedule.

GAAP NET INCOME

For the three-month period ended September 30, 2017, the Company reported a net loss of ($137.5) million, or ($0.67) per common share, on operating revenues of $219.6 million. This compares to net income of $82.1 million, or $0.40 per common share, on operating revenues of $224.6 million, for the same period in 2016.

For the nine-month period ended September 30, 2017, the Company reported net income of $39.8 million, or $0.19 per common share, on operating revenues of $687.2 million. This compares to net income of $253.5 million, or $1.26 per common share, on operating revenues of $666.3 million, for the same period in 2016.

The year-to-date decrease in net income compared to the prior year was primarily due to an increase of $198.0 million in impairments on direct financing leases, $9.7 million increase in provisions for uncollectible accounts, increases in interest expense of $20.8 million, interest refinancing costs of $19.9 million, depreciation and amortization expense of $16.0 million and a $12.4 million decrease in gains on the sale of assets. This decrease in net income was partially offset by $20.8 million of increased revenue associated with new investments completed in 2016 and 2017, a contractual settlement in the first quarter of 2017 of $10.4 million, $23.1 million reduction of impairments on real estate assets and $9.6 million decrease in acquisition costs.

CEO COMMENTS

Taylor Pickett, Omega’s Chief Executive Officer stated, “We are in active discussions with Orianna regarding the transition of some or all of their remaining portfolio to new operators. Since 2014, occupancy in the Orianna portfolio has declined from 92% to 89%. Revenue has grown by 2%, while operating expenses have grown by 6%. We believe that for some of the Orianna facilities new operators may be able to improve occupancy and reduce expenses; however, based on current facility performance, we anticipate that the current annual contractual rent of $46 million will likely be reduced to a range of $32 million to $38 million once the transition process is complete.” Mr. Pickett, continued, “The transition timing is expected to take approximately six months.”

2017 RECENT DEVELOPMENTS AND THIRD QUARTER HIGHLIGHTS

In Q4 2017, the Company

  • increased its quarterly common stock dividend rate to $0.65 per share.

In Q3 2017, the Company

  • completed $203 million in new investments.
  • transitioned Orianna’s Texas portfolio to an existing operator.
  • invested $36 million in capital renovation and construction-in-progress projects.
  • increased its quarterly common stock dividend rate to $0.64 per share.

In Q2 2017, the Company

  • entered into new and amended senior unsecured credit facilities to replace the Company’s prior unsecured revolving credit and term loan credit facilities.
  • completed $134 million in new investments.
  • invested $48 million in capital renovation and construction-in-progress projects.
  • redeemed $400 million of its 5.875% Senior Notes due 2024.
  • prepaid a $200 million senior unsecured term loan.
  • issued $550 million aggregate principal amount of its 4.75% Senior Notes due 2028.
  • issued $150 million aggregate principal amount of its 4.50% Senior Notes due 2025.
  • increased its quarterly common stock dividend rate to $0.63 per share.

In Q1 2017, the Company

  • completed $8 million in new investments.
  • invested $30 million in capital renovation and construction-in-progress projects.
  • increased its quarterly common stock dividend rate to $0.62 per share.

THIRD QUARTER 2017 RESULTS

Operating Revenues and Expenses – Operating revenues for the three-month period ended September 30, 2017 totaled $219.6 million which included $13.3 million of non-cash revenue.

Operating expenses for the three-month period ended September 30, 2017 totaled $307.9 million and consisted of $194.7 million in impairment on direct financing leases related to the Orianna portfolio, $11.9 million in provision for uncollectible accounts ($9.5 million related to Orianna), $71.9 million of depreciation and amortization expense, $17.8 million of impairment on real estate properties, $7.7 million of general and administrative expense, and $3.9 million of stock-based compensation expense.

Other Income and Expense – Other income and expense for the three-month period ended September 30, 2017 was a net expense of $49.5 million, primarily consisting of $47.4 million of interest expense and $2.2 million of amortized deferred financing costs.

Funds From Operations – For the three-month period ended September 30, 2017, FFO was a loss of ($46.8) million, or a loss of ($0.24) per common share on 207 million weighted-average common shares outstanding, compared to $162.6 million, or $0.80 per common share on 204 million weighted-average common shares outstanding, for the same period in 2016.

The $46.8 million loss of FFO for the three-month period ended September 30, 2017 includes the impact of $194.7 million in impairment on direct financing leases, $11.9 million in provision for uncollectible accounts and $3.9 million of non-cash stock-based compensation expense.

The $162.6 million of FFO for the three-month period ended September 30, 2016 includes the impact of $3.7 million of non-cash stock-based compensation expense, $2.3 million of acquisition and merger related costs, $1.8 million of interest refinancing costs and $0.5 million of non-cash revenue.

Adjusted FFO was $163.6 million, or $0.79 per common share, for the three-month period ended September 30, 2017, compared to $169.9 million, or $0.83 per common share, for the same period in 2016. For further information see the “Funds From Operations” schedule.

CFO COMMENTS

Bob Stephenson, Omega’s Chief Financial Officer commented, “During our second quarter earnings call, we stated we were closely monitoring one of our operators and may have to place them on a cash basis for revenue recognition if their performance did not improve. Since Orianna did not achieve their revised operating plan and pay their full contractual rent, we placed them on a cash basis and therefore our third quarter results, including AFFO and FAD, do not include any revenue related to Orianna.” Mr. Stephenson continued, “Since 93% of our Orianna portfolio was classified as a direct financing lease, placing them on a cash basis and initiating the process to transition some or all of their portfolio to new operators also required us to record several large provisions related to the direct financing leases during the quarter.”

FINANCING ACTIVITIES

Equity Shelf Program and Dividend Reinvestment and Common Stock Purchase Plan – During the three-month period ended September 30, 2017, the Company sold 0.8 million shares of its common stock generating $26.4 million of gross proceeds. The following table outlines shares of the Company’s common stock issued under its Equity Shelf program and its Dividend Reinvestment and Common Stock Purchase Plan in 2017:

 

Equity Shelf (At-the-Market) Program for 2017

(in thousands, except price per share)
       
Q1   Q2   Q3   Year To Date
Number of shares 228 - 490 718
Average price per share $ 31.12 $ - $ 32.62 $ 32.14
Gross proceeds $ 7,079 $ - $ 15,995 $ 23,074
 
 

Dividend Reinvestment and Common Stock Purchase Program for 2017

(in thousands, except price per share)
 
Q1   Q2   Q3   Year To Date
Number of shares 239 375 343 957
Average price per share $ 30.67 $ 33.02 $ 30.39 $ 31.49
Gross proceeds $ 7,335 $ 12,386 $ 10,415 $ 30,136
 

2017 THIRD QUARTER PORTFOLIO ACTIVITY

$239 Million of New Investments in Q3 2017 – In Q3 2017, the Company completed approximately $203 million of new investments and $36 million in capital renovations and new construction consisting of the following:

$200.4 Million Acquisition – On August 31, 2017, the Company acquired 15 skilled nursing facilities (“SNFs”) for approximately $191 million from two unrelated third parties and leased them to an existing operator. The 15 Indiana SNFs with approximately 2,074 beds were added to the existing operator’s master lease with an initial annual cash yield of 9.5% and 2.5% annual escalators. Simultaneously with the closing of the acquisition, the Company entered into a $9.4 million loan to purchase the leasehold interest in a 135 bed Indiana SNF with the same operator. The loan is cross-defaulted and cross-collateralized with the Company’s existing master lease with that operator. The loan has an initial term of 5 years and bears an initial annual interest rate of 12.0% with 2.5% annual escalators.

$2.3 Million Acquisition On August 11, 2017, the Company acquired an assisted living facility (“ALF”) for $2.3 million. The 48 bed facility located in Eastland, Texas was added to the existing operator’s master lease with an initial annual cash yield of 9.25%.

$36 Million Capital Renovation Projects – In addition to the new investments outlined above, in Q3 2017, the Company invested $36.4 million under its capital renovation and construction-in-progress programs.

ASSET TRANSFERS, IMPAIRMENTS, AND DISPOSITIONS

The Company is in active discussions with Orianna regarding the transition of some or all of their remaining portfolio to new operators. In July 2017, the Company transitioned nine Orianna SNFs in Texas to an existing operator of the Company. The nine SNFs were added to the existing master lease with that operator. The Company recorded an impairment loss of approximately $194.7 million related to its remaining direct financing lease portfolio with Orianna. The Company also recorded approximately $11.9 million of provision for uncollectible accounts during the third quarter of 2017.

During the third quarter of 2017, the Company sold four facilities for approximately $11.5 million in net cash proceeds recognizing a gain of approximately $0.7 million. Two of the sold facilities were previously classified as investment in direct financing leases and one was classified as assets held for sale. In addition, during the third quarter, the Company recorded approximately $17.8 million of impairments on six facilities to reduce the net book value of these facilities to their estimated fair value or selling price.

As of September 30, 2017, the Company had eight facilities, totaling $17.3 million, classified as assets held for sale. The Company expects to sell these facilities over the next few quarters. The Company is also evaluating over $200 million of potential disposition opportunities within our portfolio that could potentially close over the next 9 - 12 months.

DIVIDENDS

The Board of Directors declared a common stock dividend of $0.65 per share, increasing the quarterly common dividend by $0.01 per share over the previous quarter. The common dividends are to be paid November 15, 2017 to common stockholders of record as of the close of business on October 31, 2017.

2017 ADJUSTED FFO GUIDANCE REVISED

Bob Stephenson, Omega’s CFO commented, “We are lowering our 2017 guidance to reflect the temporary loss of third and fourth quarter 2017 revenue primarily related to placing Orianna and a non-top ten operator on a cash basis.”

The Company’s revised guidance for 2017 Adjusted FFO is now $3.27 to $3.28 per diluted share. The following table presents a reconciliation of Omega’s guidance regarding Adjusted FFO to projected GAAP earnings.

 
2017 Annual Adjusted FFO
Guidance Range
(per diluted common share)
Full Year
Net Income $0.62 - $0.63
Depreciation 1.37
Gain on assets sold (0.04)
Real estate impairment 0.17
FFO $2.12 - $2.13
Adjustments:
Provision for impairment on direct financing leases 0.96
Provision for uncollectible accounts 0.07
Contractual settlement (0.05)
Acquisition/transaction costs 0.00
Interest – refinancing costs 0.11
Other revenue (0.01)
Stock-based compensation expense 0.07
Adjusted FFO $3.27 - $3.28
 

Note: All per share numbers rounded to 2 decimals.

 

The Company's Adjusted FFO guidance for 2017 includes approximately $459 million of actual new investments completed to date; however, it excludes the impact of potential additional new investments. It assumes the Company will not be recording revenue related to its Orianna portfolio for the fourth quarter of 2017. It also excludes the impact of gains and losses from the sale of assets, revenue from divestitures, certain revenue and expense items, interest refinancing expense, capital transactions, acquisition costs, and additional provision for uncollectible accounts. The Company may, from time to time, update its publicly announced Adjusted FFO guidance, but it is not obligated to do so.

The Company's guidance is based on a number of assumptions, which are subject to change and many of which are outside the Company’s control. If actual results vary from these assumptions, the Company's expectations may change. Without limiting the generality of the foregoing, the timing and completion of acquisitions, divestitures, capital and financing transactions, and variations in stock-based compensation expense may cause actual results to vary materially from our current expectations. There can be no assurance that the Company will achieve its projected results.

CONFERENCE CALL

The Company will be conducting a conference call on Tuesday, October 31, 2017 at 10 a.m. Eastern to review the Company’s 2017 third quarter results and current developments. Analysts and investors within the United States interested in participating are invited to call (877) 511-2891. The Canadian toll-free dial-in number is (855) 669-9657. All other international participants can use the dial-in number (412) 902-4140. Ask the operator to be connected to the “Omega Healthcare’s Third Quarter 2017 Earnings Call.”

To listen to the conference call via webcast, log on to www.omegahealthcare.com and click the “earnings call” icon on the Company’s home page. Webcast replays of the call will be available on the Company’s website for two weeks following the call.

Omega is a real estate investment trust investing in and providing financing to the long-term care industry. As of September 30, 2017, Omega has a portfolio of investments that includes approximately 1,000 properties located in 42 states and the United Kingdom and operated by 77 different operators.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega’s expectations. Omega does not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made.

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) regulatory and other changes in the healthcare sector; (iii) changes in the financial position of Omega’s operators; (iv) the ability of any of Omega’s operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega’s mortgages and impede the ability of to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations; (v) the availability and cost of capital; (vi) changes in Omega’s credit ratings and the ratings of its debt securities; (vii) competition in the financing of healthcare facilities; (viii) Omega’s ability to maintain its status as a REIT; (ix) Omega’s ability to sell assets held for sale on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (x) Omega’s ability to re-lease, otherwise transition or sell underperforming assets (including the Orianna portfolio) on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (xi) the effect of economic and market conditions generally, and particularly in the healthcare industry; (xii) the potential impact of changes in the SNF and ALF market or local real estate conditions on the Company’s ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms and (xiii) other factors identified in Omega’s filings with the Securities and Exchange Commission. Statements regarding future events and developments and Omega’s future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward looking statements. Omega undertakes no obligation to update any forward-looking statements contained in this announcement.

   
OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

 
September 30, December 31,
  2017       2016  
(Unaudited)
ASSETS
Real estate properties
Real estate investments $ 7,977,043 $ 7,566,358
Less accumulated depreciation   (1,432,154 )     (1,240,336 )
Real estate investments – net 6,544,889 6,326,022
Investments in direct financing leases – net 364,997 601,938
Mortgage notes receivable – net   666,606       639,343  
7,576,492 7,567,303
Other investments – net 273,821 256,846
Investment in unconsolidated joint venture 37,733 48,776
Assets held for sale – net   17,324       52,868  
Total investments 7,905,370 7,925,793
 
Cash and cash equivalents 24,318 93,687
Restricted cash 10,596 13,589
Accounts receivable – net 269,746 240,035
Goodwill 644,571 643,474
Other assets   36,045       32,682  
Total assets $ 8,890,646     $ 8,949,260  
 
LIABILITIES AND EQUITY
Revolving line of credit $ 365,000 $ 190,000
Term loans – net 903,221 1,094,343
Secured borrowings – net 53,419 54,365
Unsecured borrowings – net 3,322,888 3,028,146
Accrued expenses and other liabilities 285,690 360,514
Deferred income taxes   17,589       9,906  
Total liabilities   4,947,807       4,737,274  
 
Equity:
Common stock $.10 par value authorized – 350,000 shares, issued and outstanding – 198,065 shares as of September 30, 2017 and 196,142 as of December 31, 2016

 

19,806

 

19,614

Common stock – additional paid-in capital 4,925,908 4,861,408
Cumulative net earnings 1,776,956 1,738,937
Cumulative dividends paid (3,080,999 ) (2,707,387 )
Accumulated other comprehensive loss   (34,843 )     (53,827 )
Total stockholders’ equity 3,606,828 3,858,745
Noncontrolling interest   336,011       353,241  
Total equity   3,942,839       4,211,986  
Total liabilities and equity $ 8,890,646     $ 8,949,260  

   
OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Unaudited

(in thousands, except per share amounts)

 
Three Months Ended Nine Months Ended
September 30, September 30,
  2017       2016     2017       2016  
Revenue    
Rental income $ 194,063 $ 185,837 $ 580,597 $ 548,994
Income from direct financing leases 614 15,611 31,722 46,574
Mortgage interest income 16,920 15,996 49,173 53,973
Other investment income – net 7,245 6,229 21,437 14,642
Miscellaneous income   796     965     4,250     2,158  
Total operating revenues 219,638 224,638 687,179 666,341
 
Expenses
Depreciation and amortization 71,925 68,316 212,268 196,254
General and administrative 7,688 8,755 24,275 24,599
Stock-based compensation 3,872 3,673 11,350 10,116
Acquisition costs - 2,309 (22 ) 9,584
Impairment loss on real estate properties 17,837 17,275 35,610 58,726
Impairment on direct financing leases 194,659 - 197,968 -
Provision (recovery) for uncollectible accounts   11,899     (3 )   13,667     3,967  
Total operating expenses 307,880 100,325 495,116 303,246
 
Income before other income and expense (88,242 ) 124,313 192,063 363,095
Other income (expense)
Interest income 4 157 262 169
Interest expense (47,383 ) (42,855 ) (140,509 ) (119,728 )
Interest – amortization of deferred financing costs (2,228 ) (2,502 ) (7,273 ) (6,844 )
Interest – refinancing costs - (1,815 ) (21,965 ) (2,113 )
Contractual settlement - - 10,412 -
Realized gain (loss) on foreign exchange   95     (222 )   235     (244 )
Total other expense (49,512 ) (47,237 ) (158,838 ) (128,760 )
 
(Loss) income before gain on assets sold (137,754 ) 77,076 33,225 234,335
Gain on assets sold – net   693     5,139     7,491     19,931  
(Loss) income from continuing operations (137,061 ) 82,215 40,716 254,266
Income tax expense (999 )

 

(81 ) (2,690 ) (782 )
Income from unconsolidated joint venture   545  

 

  -     1,728     -  
Net (loss) income (137,515 ) 82,134 39,754 253,484
Net loss (income) attributable to noncontrolling interest   5,837     (3,585 )   (1,735 )   (11,328 )
Net (loss) income available to common stockholders $ (131,678 ) $ 78,549   $ 38,019   $ 242,156  
 
Income per common share available to common stockholders:
Basic:
Net (loss) income available to common stockholders $ (0.67 ) $ 0.40   $ 0.19   $ 1.27  
Diluted:
Net (loss) income $ (0.67 ) $ 0.40   $ 0.19   $ 1.26  
 
Dividends declared per common share $ 0.64   $ 0.60   $ 1.89   $ 1.75  
 
Weighted-average shares outstanding, basic   197,890     194,123     197,445     190,444  
Weighted-average shares outstanding, diluted   206,662     204,078     206,502     200,528  

   
OMEGA HEALTHCARE INVESTORS, INC.
FUNDS FROM OPERATIONS
Unaudited

(in thousands, except per share amounts)

 
Three Months Ended Nine Months Ended
September 30, September 30,
  2017       2016     2017       2016  
   
Net (loss) income $ (137,515 ) $ 82,134 $ 39,754 $ 253,484
Deduct gain from real estate dispositions   (693 )   (5,139 )   (7,491 )   (19,931 )
Sub – total (138,208 ) 76,995 32,263 233,553
Elimination of non-cash items included in net income:
Depreciation and amortization 71,925 68,316 212,268 196,254
Depreciation - unconsolidated joint venture 1,657 4,973
Add back non-cash provision for impairments on real estate properties   17,837     17,275     35,610     58,726  
Funds from operations (“FFO”) $ (46,789 ) $ 162,586   $ 285,114   $ 488,533  
 
Weighted-average common shares outstanding, basic 197,890 194,123 197,445 190,444
Restricted stock and PRSUs 1,093 271 1,174
Omega OP Units   8,772     8,862     8,786     8,910  
Weighted-average common shares outstanding, diluted   206,662     204,078     206,502     200,528  
 
Funds from operations available per share $ (0.24 ) $ 0.80   $ 1.38   $ 2.44  
 
Adjustments to calculate adjusted funds from operations:
Funds from operations stockholders $ (46,789 ) $ 162,586 $ 285,114 $ 488,533
Deduct other revenue (448 ) (1,881 ) (683 )
Deduct prepayment fee income from early termination of mortgages (5,390 )
Deduct contractual settlement (10,412 )
Add back impairment for direct financing leases 194,659 197,968
Add back (deduct) provision for uncollectible accounts 11,899 (3 ) 13,667 3,967
Add back (deduct) acquisition costs 2,309 (22 ) 9,584
Add back interest refinancing expense 1,815 23,539 2,113
Add back non-cash stock-based compensation expense   3,872     3,673     11,350     10,116  
Adjusted funds from operations (“AFFO”) $ 163,641   $ 169,932   $ 519,323   $ 508,240  
 
Adjustments to calculate funds available for distribution:
Non-cash interest expense 2,200 2,555 7,861 6,834
Capitalized interest (1,972 )

 

(1,640 ) (5,867 ) (4,765 )
Non-cash revenues   (13,314 )

 

  (18,251 )   (49,399 )   (55,226 )
Funds available for distribution (“FAD”) $ 150,555   $ 152,596   $ 471,918   $ 455,083  
 

Funds From Operations (“FFO”), Adjusted FFO and Funds Available for Distribution (“FAD”) are non-GAAP financial measures. For purposes of the Securities and Exchange Commission’s Regulation G, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that exclude amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or include amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Regulation G, the Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company calculates and reports FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts ("NAREIT"), and consequently, FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. The Company believes that FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. The term FFO was designed by the real estate industry to address this issue. FFO described herein is not necessarily comparable to FFO of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

Adjusted FFO is calculated as FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items identified above. FAD is calculated as Adjusted FFO less non-cash interest expense and non-cash revenue, such as straight-line rent. The Company believes these measures provide an enhanced measure of the operating performance of the Company’s core portfolio as a REIT. The Company’s computation of Adjusted FFO and FAD are not comparable to the NAREIT definition of FFO or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.

The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business. The Company also uses Adjusted FFO among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO can facilitate comparisons of operating performance between periods and between other REITs. The Company offers these measures to assist the users of its financial statements in analyzing its operating performance and not as measures of liquidity or cash flow. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP. Investors and potential investors in the Company’s securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.

The following tables present selected portfolio information, including operator and geographic concentrations, and revenue maturities for the period ended September 30, 2017:

       
As of September 30, 2017 As of September 30, 2017
Balance Sheet Data

Total # of
Properties (2)

 

Total
Investment
($000’s)

 

% of
Investment

# of Operating
Properties(4)

 

# of Operating
Beds

Real Estate Investments (1) 910   $ 7,996,243   89 % 907   90,949
Direct Financing Leases 42 364,997 4 % 41 4,204
Mortgage Notes Receivable 52     663,411   7 % 51   5,366
Total Investments 1,004 $ 9,024,651 100 % 999 100,519
                       
Investment Data

Total # of
Properties (2)

 

Total
Investment
($000’s)

 

% of
Investment

# of Operating
Properties(4)

 

# of
Operating
Beds

 

Investment
per Bed
($000’s)

Skilled Nursing Facilities/Transitional Care (1)

869

 

$

7,551,841

 

84

%

869

 

92,451

 

$

82

Senior Housing (1) (3) 135     1,472,810   16 % 130   8,068 $ 183
1,004 $ 9,024,651 100 % 999 100,519 $ 90
 
(1) Total Investment includes a $19.2 million lease inducement and excludes $17.3 million (eight properties) classified as assets held for sale.
(2) Total # of Properties excludes eight properties classified as assets held for sale.
(3) Includes ALFs, memory care and independent living facilities.
(4) Total # of Operating Properties excludes facilities which are non-operating, closed and/or not currently providing patient services.
         
Revenue Composition ($000's)
             
Revenue by Investment Type Three Months Ended Nine Months Ended
September 30, 2017   September 30, 2017
Rental Property $ 194,063 88 % $ 580,597 84 %
Direct Financing Leases 614 0 % 31,722 5 %
Mortgage Notes 16,920 8 % 49,173 7 %
Other Investment Income and Miscellaneous Income - net   8,041   4 %     25,687   4 %
$ 219,638 100 % $ 687,179 100 %
             
Revenue by Facility Type Three Months Ended   Nine Months Ended
September 30, 2017   September 30, 2017
Skilled Nursing Facilities/Transitional Care $ 183,534   84 % $ 582,256   84 %
Senior Housing 28,063 12 % 79,236 12 %
Other   8,041   4 %     25,687   4 %
$ 219,638 100 % $ 687,179 100 %
             
Rent/Interest Concentration by Operator

($000’s)

# of
Properties (1)

 

Total
Annualized
Contractual
Rent/Interest (2)

 

% of Total
Annualized
Contractual
Rent/Interest

Ciena Healthcare 70   $ 86,237   9.8 %
CommuniCare Health Services, Inc. 47 66,684 7.6 %
Signature Holdings II, LLC 62 58,784 6.7 %
Genesis Healthcare 50 57,614 6.6 %
Orianna (f/k/a New Ark Investment, Inc.) 42 46,103 5.2 %
Saber Health Group 44 40,653 4.6 %
Maplewood Real Estate Holdings, LLC 14 36,414 4.1 %
Health & Hospital Corporation 44 34,774 4.0 %
Guardian LTC Management Inc. 31 29,819 3.4 %
Diversicare Healthcare Services 35 28,249 3.2 %
Remaining 67 Operators 560     393,646   44.8 %
999 $ 878,977 100.0 %
(1)   Number of properties excludes facilities which are non-operating, closed and/or not currently providing patient services.
(2) 3Q 2017 contractual rent/interest annualized; includes mezzanine and term loan interest.
             
Geographic Concentration by Investment ($000’s)

Total # of
Properties (1)

 

Total Investment (2)

 

% of Total
Investment

Ohio 86   $ 844,799   9.4 %
Florida 95 800,588 8.9 %
Texas 109 776,633 8.6 %
Michigan 49 623,781 6.9 %
Indiana 74 617,491 6.8 %
California 54 496,980 5.5 %
Pennsylvania 43 469,608 5.2 %
Tennessee 41 327,289 3.6 %
North Carolina 32 264,951 2.9 %
Virginia 17 262,205 2.9 %
Remaining 32 states (3) 351     3,136,485   34.8 %
951 8,620,810 95.5 %
United Kingdom 53     403,841   4.5 %
1,004 $ 9,024,651 100.0 %
 
(1) Total # of Properties excludes eight properties classified as assets held for sale.
(2) Total Investment includes a $19.2 million lease inducement and excludes $17.3 million (eight properties) classified as assets held for sale.
(3) # of states and Total Investment includes New York City 2nd Avenue development project.
     
Rent and Loan Maturities ($000's) As of September 30, 2017
Operating Lease Expirations

& Loan Maturities

Year  

2017 Lease
Rent

 

2017
Interest

 

2017 Lease
and Interest
Rent

  %
2017   $ 217   $ 457   $ 674   0.1 %
2018 8,557 2,078 10,635 1.2 %
2019 3,207 - 3,207 0.4 %
2020 5,615 5,923 11,538 1.3 %
2021 10,029 956 10,985 1.2 %
2022 64,703 2,943 67,646 7.7 %
 
Note: Based on annualized 3rd quarter 2017 contractual rent and interest.
 

The following tables present operator revenue mix, census and coverage data based on information provided by our operators as of June 30, 2017:

     
Operator Revenue Mix As of June 30, 2017
Medicaid  

Medicare /
Insurance

  Private / Other
   
Three-months ended June 30, 2017 51.9 % 35.9 % 12.2 %
Three-months ended March 31, 2017 51.0 % 37.3 % 11.7 %
Three-months ended December 31, 2016 52.6 % 35.8 % 11.6 %
Three-months ended September 30, 2016 53.0 % 35.8 % 11.2 %
Three-months ended June 30, 2016 51.8 % 37.5 % 10.7 %
       
Operator Census and Coverage     Coverage Data
Occupancy (1)  

Before

Management
Fees

 

After

Management
Fees

 
Twelve-months ended June 30, 2017 82.4 % 1.71x 1.34x
Twelve-months ended March 31, 2017 82.5 % 1.69x 1.33x
Twelve-months ended December 31, 2016 82.2 % 1.69x 1.33x
Twelve-months ended September 30, 2016 82.1 % 1.68x 1.31x
Twelve-months ended June 30, 2016 82.1 % 1.72x 1.34x
 
(1) Based on available (operating) beds.
 

The following table presents a debt maturity schedule as of September 30, 2017:

           

Debt
Maturities
($000’s)

Secured Debt   Unsecured Debt
Year

HUD
Mortgages (1)

 

Line of Credit
and Term Loans
(2)(3)

 

Senior
Notes/Other
(4)

 

Sub Notes
(5)

 

Total Debt
Maturities

2017 $ -   $ -   $ -   $ - $ -
2018 - - - - -
2019 - - - - -
2020 - - - - -
2021 - 1,250,000 - 20,000 1,270,000
2022 - 908,980 - - 908,980
Thereafter   53,992     -     3,350,000     -     3,403,992
$ 53,992   $ 2,158,980   $ 3,350,000   $ 20,000   $ 5,582,972
 
(1) Mortgages guaranteed by HUD (excluding net deferred financing costs of $0.6 million).
(2) Reflected at 100% borrowing capacity.
(3) $1.25 billion excludes a $700 million accordion feature and $6.0 million net deferred financing costs. The $909 million is comprised of a: $425 million U.S. Dollar term loan, £100 million term loan (equivalent to $134.0 million in US dollars), $100 million term loan to Omega’s operating partnership and $250 million 2015 term loan (excludes $5.8 million net deferred financing costs) assuming the exercise of existing extension rights.
(4) Excludes net discounts, deferred financing costs and a $1.5 million promissory note.
(5) Excludes $0.4 million of fair market valuation adjustments.
 

The following table presents investment activity for the three– and nine– month period ended September 30, 2017:

         
Investment Activity ($000's) Three Months Ended   Nine Months Ended
September 30, 2017   September 30, 2017
Funding by Investment Type $ Amount   %   $ Amount   %
Real Property $ 193,294   80.9 % $ 324,271   70.7 %
Construction-in-Progress 21,275 8.9 % 63,371 13.8 %
Capital Expenditures 12,925 5.4 % 43,574 9.5 %
Investment in Direct Financing Leases 2,184 0.9 % 6,951 1.5 %
Mortgages - 0.0 % 11,000 2.4 %
Other   9,442   3.9 %     9,442   2.1 %
Total $ 239,120 100.0 % $ 458,609 100.0 %

Omega Healthcare Investors, Inc.
Bob Stephenson, CFO, 410-427-1700



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today